|

Trastuzumab (Herceptin) Clinical Trials

3 actively recruiting trials across 1 location

No change since June 2026

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Sun Yat-sen University1
  • Institut Curie1
  • Alliance for Clinical Trials in Oncology1

Indications

  • Breast Cancer3
  • Cancer3
  • Early-stage HER2+ Breast Cancer1
  • Unresectable Breast Cancer1
  • Early Stage Breast Carcinoma1

Other2 trials

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Phase 2
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Phase 2

Phoenix, Arizona1 trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Cancer Center at Saint Joseph's

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.